Mets sticking with struggling Frank Francisco as closer

3 Comments

Back-to-back ugly outings over the weekend left Frank Francisco with an 8.56 ERA, which along with three losses and two blown saves overall this season led to speculation that the Mets were considering a closer change.

Instead manager Terry Collins said today that he’s sticking with Francisco and the team believes his struggles might stem from tipping his pitches, with the idea being that the issue is fixable.

Francisco’s pre-2012 track record as a setup man and occasional closer suggested he was very capable of getting the job done in the ninth inning on a full-time basis, but injuries have clouded that somewhat and his fastball velocity is also down slightly from past years.

Francisco has missed plenty of bats, totaling 15 strikeouts in 13.2 innings, but he’s also handed out seven walks and opponents are hitting .328. Last year with the Blue Jays he had a 3.55 ERA and 53/18 K/BB ratio in 51 innings, so it’s not just blind faith from Collins keeping him in the role … for now, at least. In the meantime Jon Rauch looms as the obvious fallback option.

MLB, union resume blood testing after pandemic, lockout

Scott Taetsch-USA TODAY Sports
1 Comment

NEW YORK – In the first acknowledgment that MLB and the players’ association resumed blood testing for human growth hormone, the organizations said none of the 1,027 samples taken during the 2022 season tested positive.

HGH testing stopped in 2021 because of the COVID-19 pandemic. Testing also was halted during the 99-day lockout that ended in mid-March, and there were supply chain issues due to COVID-19 and additional caution in testing due to coronavirus protocols.

The annual public report is issued by Thomas M. Martin, independent program administrator of MLB’s joint drug prevention and treatment program. In an announcement accompanying Thursday’s report, MLB and the union said test processing is moving form the INRS Laboratory in Quebec, Canada, to the UCLA Laboratory in California.

MLB tests for HGH using dried blood spot testing, which was a change that was agreed to during bargaining last winter. There were far fewer samples taken in 2022 compared to 2019, when there were 2,287 samples were collected – none positive.

Beyond HGH testing, 9,011 urine samples were collected in the year ending with the 2022 World Series, up from 8,436 in the previous year but down from 9,332 in 2019. And therapeutic use exemptions for attention deficit hyperactivity disorder dropped for the ninth straight year, with just 72 exemptions in 2022.

Overall, the league issued six suspensions in 2022 for performance-enhancing substances: three for Boldenone (outfielder/first baseman Danny Santana, pitcher Richard Rodriguez and infielder Jose Rondon, all free agents, for 80 games apiece); one each for Clomiphene (Milwaukee catcher Pedro Severino for 80 games), Clostebol (San Diego shortstop Fernando Tatis Jr. for 80 games) and Stanozolol (Milwaukee pitcher J.C. Mejia for 80 games).

There was an additional positive test for the banned stimulant Clobenzorex. A first positive test for a banned stimulant results in follow-up testing with no suspension.